Zura Bio Limited (NASDAQ:ZURA – Get Free Report) was up 17.2% on Friday . The stock traded as high as $5.25 and last traded at $5.32. Approximately 985,066 shares changed hands during mid-day trading, an increase of 34% from the average session volume of 737,134 shares. The stock had previously closed at $4.54.
Wall Street Analysts Forecast Growth
A number of research firms recently issued reports on ZURA. Oppenheimer dropped their price objective on Zura Bio from $16.00 to $15.00 and set an “outperform” rating for the company in a report on Friday, March 20th. Chardan Capital increased their target price on Zura Bio from $10.00 to $11.00 and gave the stock a “buy” rating in a research note on Monday, March 23rd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Zura Bio in a research report on Wednesday, April 8th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Zura Bio presently has an average rating of “Moderate Buy” and an average target price of $10.75.
Read Our Latest Report on ZURA
Zura Bio Stock Up 17.1%
Zura Bio (NASDAQ:ZURA – Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.05). As a group, equities research analysts forecast that Zura Bio Limited will post -0.76 earnings per share for the current year.
Hedge Funds Weigh In On Zura Bio
Institutional investors have recently made changes to their positions in the company. Commodore Capital LP bought a new stake in shares of Zura Bio in the first quarter valued at about $19,338,000. Siren L.L.C. increased its position in Zura Bio by 187.3% during the 1st quarter. Siren L.L.C. now owns 3,734,866 shares of the company’s stock valued at $22,222,000 after purchasing an additional 2,434,866 shares during the period. JPMorgan Chase & Co. increased its position in Zura Bio by 78.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 4,659,951 shares of the company’s stock valued at $4,893,000 after purchasing an additional 2,052,732 shares during the period. EcoR1 Capital LLC bought a new stake in shares of Zura Bio in the 1st quarter valued at about $7,019,000. Finally, Boothbay Fund Management LLC purchased a new stake in shares of Zura Bio in the 3rd quarter worth approximately $3,568,000. Hedge funds and other institutional investors own 61.14% of the company’s stock.
Zura Bio Company Profile
Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.
The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.
Featured Articles
- Five stocks we like better than Zura Bio
- Rocket Lab’s NASA Win Tests Key Support After Sharp Pullback
- AST SpaceMobile Just Nailed a Major Launch—So Why Is the Stock Crashing?
- Palantir’s Valuation Problem Just Met 2 New Growth Catalysts
- Xcel Energy Stock Offers Stability as Electricity Demand Builds
Receive News & Ratings for Zura Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zura Bio and related companies with MarketBeat.com's FREE daily email newsletter.
